Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways articleshttps://www.targetedonc.com/newsTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways articles© 2026 MJH Life Sciences™ and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.Mon, 26 Oct 2026 22:42:00 +00005en-us14447https://www.targetedonc.com/newshttps://www.targetedonc.com/logo.webphttps://www.targetedonc.com/view/enzomenib-earns-fda-breakthrough-status-in-kmt2a-rearranged-leukemiahttps://www.targetedonc.com/view/enzomenib-earns-fda-breakthrough-status-in-kmt2a-rearranged-leukemia<![CDATA[The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.]]>Mon, 26 Oct 2026 20:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/fda-approves-talazoparib-enzalutamide-in-hrr-mutated-prostate-cancerhttps://www.targetedonc.com/view/fda-approves-talazoparib-enzalutamide-in-hrr-mutated-prostate-cancer<![CDATA[The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings. ]]>Mon, 26 Oct 2026 18:44:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/sacituzumab-tirumotecan-shows-survival-benefit-in-advanced-endometrial-cancerhttps://www.targetedonc.com/view/sacituzumab-tirumotecan-shows-survival-benefit-in-advanced-endometrial-cancer<![CDATA[Domenica Lorusso, MD, PhD, discusses phase 3 findings on sacituzumab tirumotecan in advanced or recurrent endometrial cancer.]]>Mon, 26 Oct 2026 18:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/esmo-2026-presidential-symposium-iii-artemis-011-trofuse-005-keynote-c93-moiohttps://www.targetedonc.com/view/esmo-2026-presidential-symposium-iii-artemis-011-trofuse-005-keynote-c93-moio<![CDATA[ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.]]>Mon, 26 Oct 2026 18:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/pembrolizumab-alone-exceeds-chemo-first-line-dmmr-endometrial-cancerhttps://www.targetedonc.com/view/pembrolizumab-alone-exceeds-chemo-first-line-dmmr-endometrial-cancer<![CDATA[Brian M. Slomovitz, MD, discusses the outcomes of the KEYNOTE-C93 trial of pembrolizumab for endometrial cancer. ]]>Mon, 26 Oct 2026 17:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/esmo-2026-gi-cancer-trial-updates-survival-immunotherapyhttps://www.targetedonc.com/view/esmo-2026-gi-cancer-trial-updates-survival-immunotherapy<![CDATA[ESMO 2026 unveils GI cancer advances: targeted and immunotherapy regimens boost survival in pancreatic, colorectal, gastric, and HER2+ gastroesophageal disease.]]>Mon, 26 Oct 2026 16:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/niazi-on-practice-changing-data-in-prostate-cancer-from-esmo-2026https://www.targetedonc.com/view/niazi-on-practice-changing-data-in-prostate-cancer-from-esmo-2026<![CDATA[Tamim Niazi, MDCM, discusses key findings from the phase 3 DASL-HiCaP study presented at the 2026 ESMO Congress.]]>Mon, 26 Oct 2026 14:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/jacob-sands-tarlatamab-durvalumab-dellphi-305-esmo-2026https://www.targetedonc.com/view/jacob-sands-tarlatamab-durvalumab-dellphi-305-esmo-2026<![CDATA[Dr Jacob Sands discusses first-look OS and PFS data for tarlatamab plus durvalumab maintenance from the phase 3 DeLLphi-305 trial at ESMO 2026.]]>Mon, 26 Oct 2026 13:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1<![CDATA[ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.]]>Sun, 25 Oct 2026 19:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/olomorasib-combination-manageable-liver-toxicity-kras-g12c-mutant-nsclchttps://www.targetedonc.com/view/olomorasib-combination-manageable-liver-toxicity-kras-g12c-mutant-nsclc<![CDATA[Marcelo Vailati Negrao, MD, discusse safety outcomes with first-line olomorasib plus chemoimmunotherapy in LOXO-RAS-20001 and SUNRAY-01.]]>Sun, 25 Oct 2026 18:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/bridgewater-weighs-potential-sequencing-after-ivonescimab-and-the-future-of-btc-therapyhttps://www.targetedonc.com/view/bridgewater-weighs-potential-sequencing-after-ivonescimab-and-the-future-of-btc-therapy<![CDATA[John Bridgewater, BA, MBBS, MRCP, PhD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced biliary tract cancer. ]]>Sun, 25 Oct 2026 17:43:25 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/key-takeaways-from-dellphi-305-at-esmo-2026https://www.targetedonc.com/view/key-takeaways-from-dellphi-305-at-esmo-2026<![CDATA[Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as first-line maintenance in SCLC.]]>Sun, 25 Oct 2026 17:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/ctdna-analysis-cemiplimab-benefit-mrd-subgroups-in-cscchttps://www.targetedonc.com/view/ctdna-analysis-cemiplimab-benefit-mrd-subgroups-in-cscc<![CDATA[Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.]]>Sun, 25 Oct 2026 15:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/lu-177-psma-retreatment-interim-safety-esmo-mcrpchttps://www.targetedonc.com/view/lu-177-psma-retreatment-interim-safety-esmo-mcrpc<![CDATA[Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer. ]]>Sun, 25 Oct 2026 14:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/rahul-winayak-emerging-therapeutic-targets-metastatic-renal-cell-carcinomahttps://www.targetedonc.com/view/rahul-winayak-emerging-therapeutic-targets-metastatic-renal-cell-carcinoma<![CDATA[Rahul Winayak, MD, explains new mRCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome immunotherapy resistance.]]>Sat, 24 Oct 2026 19:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/ixotatug-vedotin-claudin-6-adc-germ-cell-tumors-darren-feldmanhttps://www.targetedonc.com/view/ixotatug-vedotin-claudin-6-adc-germ-cell-tumors-darren-feldman<![CDATA[Darren Feldman, MD, discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated germ cell tumors, with manageable ADC safety and potential phase 2 plans.]]>Sat, 24 Oct 2026 17:30:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/esmo-2026-presidential-symposium-i-late-breaking-recaphttps://www.targetedonc.com/view/esmo-2026-presidential-symposium-i-late-breaking-recap<![CDATA[Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.]]>Sat, 24 Oct 2026 16:18:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/shannon-westin-b7-h4-adc-biomarker-testing-toxicity-sequencinghttps://www.targetedonc.com/view/shannon-westin-b7-h4-adc-biomarker-testing-toxicity-sequencing<![CDATA[Shannon Westin, MD, MPH, weighs in on B7-H4 ADCs in gynecologic cancers, focusing on testing, toxicity in maintenance use, and sequencing amid resistance, target shifts, and expanding options.]]>Sat, 24 Oct 2026 15:15:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/dr-hannah-rose-naughton-on-de-escalating-breast-cancer-treatmenthttps://www.targetedonc.com/view/dr-hannah-rose-naughton-on-de-escalating-breast-cancer-treatment<![CDATA[Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and improves quality of life.]]>Fri, 23 Oct 2026 20:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/dr-sherry-shen-on-histology-specific-trials-in-lobular-breast-cancerhttps://www.targetedonc.com/view/dr-sherry-shen-on-histology-specific-trials-in-lobular-breast-cancer<![CDATA[Sherry Shen, MD, explains why invasive lobular breast cancer needs histology-specific clinical trials and how its unique biology shapes care.]]>Fri, 23 Oct 2026 19:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/sunvozertinib-now-available-in-us-for-egfr-exon-20-insertion-nsclchttps://www.targetedonc.com/view/sunvozertinib-now-available-in-us-for-egfr-exon-20-insertion-nsclc<![CDATA[Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.]]>Fri, 23 Oct 2026 18:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/how-is-targeted-therapy-changing-non-small-cell-lung-cancer-treatment-https://www.targetedonc.com/view/how-is-targeted-therapy-changing-non-small-cell-lung-cancer-treatment-<![CDATA[Matthew Gubens, MD, explains how targeted therapies are moving into earlier-stage NSCLC, while molecular testing and resistance profiling guide treatment.]]>Fri, 23 Oct 2026 17:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/vopimetostat-plus-daraxonrasib-yields-82-orr-in-mtap-deleted-pdachttps://www.targetedonc.com/view/vopimetostat-plus-daraxonrasib-yields-82-orr-in-mtap-deleted-pdac<![CDATA[Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer. ]]>Fri, 23 Oct 2026 16:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/rilvegostomig-combo-helped-some-patients-avoid-chemotherapy-in-early-breast-cancerhttps://www.targetedonc.com/view/rilvegostomig-combo-helped-some-patients-avoid-chemotherapy-in-early-breast-cancer<![CDATA[The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors. ]]>Fri, 23 Oct 2026 15:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/early-survivorship-care-head-neck-cancer-treatment-adherence-survivalhttps://www.targetedonc.com/view/early-survivorship-care-head-neck-cancer-treatment-adherence-survival<![CDATA[Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.]]>Fri, 23 Oct 2026 14:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/personalized-mrna-vaccine-intismeran-autogene-pembrolizumab-cuts-melanoma-recurrencehttps://www.targetedonc.com/view/personalized-mrna-vaccine-intismeran-autogene-pembrolizumab-cuts-melanoma-recurrence<![CDATA[Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.]]>Fri, 23 Oct 2026 10:47:17 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/choosing-cll-therapy-around-molecular-risk-comorbidities-and-patient-preferencehttps://www.targetedonc.com/view/choosing-cll-therapy-around-molecular-risk-comorbidities-and-patient-preference<![CDATA[Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.]]>Thu, 22 Oct 2026 21:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/fda-grants-traditional-approval-pembrolizumab-tmb-high-solid-tumorshttps://www.targetedonc.com/view/fda-grants-traditional-approval-pembrolizumab-tmb-high-solid-tumors<![CDATA[The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.]]>Thu, 22 Oct 2026 19:17:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/rgenta-phase-3-alignment-rgt-61159-adenoid-cystic-carcinomahttps://www.targetedonc.com/view/rgenta-phase-3-alignment-rgt-61159-adenoid-cystic-carcinoma<![CDATA[Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027. ]]>Thu, 22 Oct 2026 18:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articleshttps://www.targetedonc.com/view/fda-grants-fast-track-status-to-sbe303-in-urothelial-cancerhttps://www.targetedonc.com/view/fda-grants-fast-track-status-to-sbe303-in-urothelial-cancer<![CDATA[The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin. ]]>Thu, 22 Oct 2026 16:00:00 GMTTargeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysusTargeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Articles